ADRB2 Arg16Gly (rs1042713): what your beta-2 receptor gene really does for fat burning and exercise
One amino acid that gets sold as a fat-loss verdict. The real effect is small, and the action is mostly the same either way.
ADRB2 builds the main receptor your body uses to pull fat out of fat cells. When adrenaline shows up during exercise or a fast, it docks onto this beta-2 receptor and flips on lipolysis: the breakdown of stored fat into free fatty acids your muscles can actually burn. It is the dominant fat-releasing receptor in human white fat, which is exactly why a common variant in this gene, rs1042713 (the one people call Arg16Gly), gets marketed as the gene that decides whether you torch fat or store it. The real story is quieter and more useful.
What ADRB2 does
The receptor sits on the surface of your fat cells like a doorbell for adrenaline. Press it and fat comes out. The Arg16Gly variant changes one amino acid right at the start of the receptor, at position 16, and that small change tweaks how the receptor behaves once adrenaline keeps pressing on it. In controlled lab work where researchers infuse a beta-agonist and measure what comes out of the fat, the Arg16 form shows a blunted rise in free fatty acids and glycerol and a bit less fat oxidation, more so in women than men. So there is a genuine signal at the level of the cell. The catch is what happens when you leave the lab.
When you move from a tightly controlled infusion to a person doing cardio three times a week, the single-gene signal gets buried. Your diet, your training, how hard you actually push, and dozens of other genes all pull on the same outcome. A small built-in difference in how fast your fat cells answer the doorbell is easy to swamp with consistent work. That is the part the marketing skips.
Your variants, decoded
Swaps one amino acid (position 16) at the start of the beta-2 receptor, which changes how the receptor behaves under repeated adrenaline. Often pitched as the fat-burning variant. On its own, it mostly is not. Here the G allele codes glycine (Gly16) and the A allele codes arginine (Arg16).
| GG | Gly16/Gly16, the more common form in many groups. The more responsive setup: under direct beta-agonist stimulation in the lab, the glycine form shows the fuller rise in free fatty acids and fat oxidation. In real training, the everyday difference is small. |
| GA | One copy of each, glycine and arginine. Intermediate, and where a lot of people land. No reliable real-world advantage or penalty for exercise fat loss. |
| AA | Arg16/Arg16. In controlled studies that infused a beta-agonist and measured fat release directly, this arginine form showed a blunted rise in free fatty acids and glycerol and a bit less fat oxidation, more so in women. It is a modest cellular difference under drug stimulation, not a measured penalty you would feel during normal training. |
Genotypes are shown order-insensitively and on the forward strand; your own export may print the complementary letters — the meaning is the same.
What the research suggests
Train your cardio consistently, with intervals in the mix. Exercise is the lever that actually moves fat through the beta-2 receptor no matter which ADRB2 version you carry. In a controlled study that infused a beta-agonist and measured fat release directly, the Arg16 form of this receptor showed a blunted rise in free fatty acids and glycerol and a bit less fat oxidation, more so in women than men. Real cellular difference. But it shows up under drug stimulation, not as a measured penalty in everyday training, and no supplement reliably changes how this receptor answers adrenaline. So the honest action for every genotype is the same: keep aerobic training consistent, lean on intervals to drive the adrenaline-to-lipolysis pathway, and let consistency outweigh the small genetic lean. An Arg/Arg result is a reason to be patient, not a reason to buy anything.
PubMed 17130852 · Jocken et al., Int J Obes (Lond) 2007;31(5):813-9: under stepwise infusion of the beta-agonist isoprenaline, the ADRB2 Arg16 allele tracked with a blunted increase in circulating free fatty acids and glycerol and decreased fat oxidation during beta-adrenergic stimulation, with the effect stronger in women than men
Educational only — not medical advice. “General evidence” means the finding is real but the supplement’s benefit isn’t unique to your genotype.
See this matched to your own DNA — free.
Upload your 23andMe or AncestryDNA file and get your actual ADRB2 result, plus every other actionable variant — each line cited, your file never stored.
Questions
Does the ADRB2 Arg16Gly variant make me a worse fat burner?
On its own, not in a way you would feel. In controlled studies that infuse a beta-agonist and measure fat release directly, the Arg16 form shows a blunted rise in free fatty acids and a touch less fat oxidation, more so in women than men. That is a real cellular difference. But when this kind of variant gets tested against actual exercise and diet, training consistency swamps it. Treat it as a small lean in your wiring, not a sentence.
What should I actually do with my ADRB2 result?
Use it as a nudge toward the basics, not a reason to buy anything. Everyone improves fat mobilization with consistent aerobic training, and intervals in particular drive the exact adrenaline-to-fat-cell pathway this gene controls. If anything, an Arg/Arg (AA) result is a small argument for being patient and letting consistency do its job. No supplement reliably changes how this receptor behaves.
My 23andMe shows different letters than this page. Did I read it wrong?
Probably not. Consumer reports sometimes list this SNP on the opposite DNA strand, so a G here can show up as a C and an A as a T in your export. The genotype and its meaning do not change, only the way the letters are printed. Match by the amino acid (Gly16 versus Arg16) rather than the raw letter if you are unsure.